Value Adjusted for Debt and Cash: Aclaris Therapeutics (ACRS)
Aclaris Therapeutics (ACRS) specializes in developing treatments for immune-inflammatory pathologies, mitigating risks by simultaneously studying molecules for rheumatology and dermatology. This chart of Enterprise Value price action reflects 494.67. The biopharmaceutical business relies on US research centers and a promising drug pipeline. The company's current stability is based on the efficacy of kinase inhibitors and licensing payments coupled with moderate R&D expenses.
Aclaris Therapeutics (ACRS) - metric breakdowns and financial figures
- current quotes and average value forecast:
- company stock exchange capitalization indicators:
- book capitalization information:
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Aclaris Therapeutics|ACRS - Long-Term Debt to Capital|Short-Term Debt to Capital aclaristx.com|ACRS - Company Debts|Debt to Net Assets Ratio Aclaris Therapeutics|ACRS - Company Long-Term Debt|Company Current Liabilities Aclaris Therapeutics|Quick Ratio aclaristx.com
- company profitability and valuation multiples indicators:
Analysis of all company metrics:Aclaris Therapeutics Inc.
Enterprise value reflects the actual entry threshold for a strategic buyer, which is critical for Aclaris Therapeutics (ACRS) amid the aggressive acquisition of biotech startups by pharma behemoths. The company's total market valuation sums capitalization and debt while subtracting liquid assets, allowing an investor to assess the actual buyout price of the business, accounting for its financial leverage and cash reserves.
Competitors of Aclaris Therapeutics (ACRS)
ARGX - Real Price to Acquire Entire Company|BNTX - Total Company Value|Value Adjusted for Debt and Cash ABVX (Abivax Pharma)|ADMA Biologics (ADMA) - Total Company Value|PTGX - Company Buyout Price|Total Company Value Immunovant|Kiniksa Pharmaceuticals, Ltd. - Full Business Value|Enterprise Value GRFS|ADPT (Adaptive Biotechnologies Inc.) - Value Adjusted for Debt and Cash|Enterprise Value CLDX (Celldex Therapeutics)|Enterprise Value auriniapharma.com AUPH|BCRX - Total Company Value|Value Adjusted for Debt and Cash VERA (Vera Therapeutics Inc)|Dianthus Pharma (DNTH) - Total Company Value|Real Price to Acquire Entire Company Pharvaris Pharma|ABCL (AbCellera Biologics Inc) - Enterprise Value|Enterprise Value tourmalinebio.com|Real Price to Acquire Entire Company PGEN (Precigen)|PHAR (Pharming Group NV) - Value Adjusted for Debt and Cash|Enterprise Value NKTR (Nektar)|Company Buyout Price Upstream Pharma (UPB)|ZBIO - Total Company Value|immunome.com (IMNM) - Real Price to Acquire Entire Company|Gossamer Bio (GOSS) - Total Company Value|Real Price to Acquire Entire Company KalVista Pharma|Real Price to Acquire Entire Company SEPN|Enterprise Value Pieris Corp|Total Company Value Savara Inc. (SVRA)|rigel.com - Business Value|Enterprise Value ANAB (AnaptysBio)|Astria Therapeutics Inc (ATXS) - Total Enterprise Value|enGene Bio - Enterprise Value|RAPT - Enterprise Value|JBIO: Enterprise Value|Real Price to Acquire Entire Company kyvernatx.com|Total Company Value Tiziana Life Sciences Ltd|Total Company Value CABA|Enterprise Value VTYX|Enterprise Value Theratechnologies, Inc (THTX)|Total Company Value Avalo Therapeutics, Inc AVTX|Value Adjusted for Debt and Cash ELDN|Agenus Inc. - Enterprise Value|Company Buyout Price Climb Bio Inc. CLYM|Zura Bio (ZURA) - Total Company Value|ATYR - Company Buyout Price|Real Price to Acquire Entire Company ADAG|IMA: Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company STTK (Shattuck Labs, Inc.)|Aggregate Business Value EQ|Enterprise Value CNTB (Connect Biopharma Holdings Limited)|Value Adjusted for Debt and Cash IMUX|Atara Biotherapeutics Inc - Enterprise Value|Total Enterprise Value InflaRx N.V.|X4 Pharmaceuticals, Inc. (XFOR) - Total Company Value|Adicet Bio, Inc. - Value Adjusted for Debt and Cash|CELU (Celularity Inc) - Enterprise Value|Enterprise Value INmune Bio Corporation|Total Company Value Barinthus Biotherapeutics (BRNS)|KZR: Full Business Value|Enterprise Value SABS (SAB Biotherapeutics, Inc.)|Akari Therapeutics PLC (AKTX) - Total Enterprise Value|ENLV: Real Price to Acquire Entire Company|QTTB - Enterprise Value|GOVX (GeoVax Labs, Inc.) - Real Price to Acquire Entire Company|EDSA: Aggregate Business Value|IBIO (iBio) - Enterprise Value|Carisma Tx (CARM) - Company Buyout Price|Enterprise Value XTLB|Real Price to Acquire Entire Company boltbio.com BOLT|Total Company Value HCW Biologics HCWB|Company Buyout Price Aptevo Therapeutics, Inc. (APVO)|AIM ImmunoTech Inc. - Enterprise Value|ADTX - Enterprise Value|GRI: Enterprise Value|Real Price to Acquire Entire Company XORTX Corp|Total Company Value Vyome Holdings Inc|REVB: Value Adjusted for Debt and Cash|Total Company Value Indaptus Therapeutics, Inc. (INDP)|Company Buyout Price Scinai Immunotherapeutics Ltd|Total Company Value CalciMedica CALI|AFMD (Affimed NV) - Full Business Value|Allakos Therapeutics - Enterprise Value|Value Adjusted for Debt and Cash HOOK (HOOKIPA Pharma Inc.)|IGMS: Enterprise Value|iTeos Therapeutics Inc (ITOS) - Enterprise Value|Total Company Value Ocean Bio|TCBP: Value Adjusted for Debt and Cash|Total Company Value Third Harmonic Bio (THRD)